AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $27.26 per share for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2015-02-24
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-09-30 was $31.14, a 91.04% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-06-30 was $27.84, a 304.65% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-03-31 was $21.81, a 1066.31% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-09-30 was $16.30.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $27.26, a 173.69% increase from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was $9.96, a 376.56% increase from fiscal 2012.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2012 was $2.09, a 375.00% increase from fiscal 2011.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2011 was $0.44.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2014-12-31 | $27.26 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $31.14 10-Q · filed 2014-11-07 | $24.30 10-Q · filed 2014-11-07 | ||
| 2014-06-30 | $27.84 10-Q · filed 2014-08-07 | $23.64 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | $21.81 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $9.96 10-K · filed 2015-02-24 | |||
| 2013-09-30 | $16.30 10-Q · filed 2014-11-07 | $9.83 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $6.88 10-Q · filed 2014-08-07 | $6.88 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $1.87 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $2.09 10-K · filed 2015-02-24 | |||
| 2011-12-31 | $0.44 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |